HLA-B*5701 & B2M

Product Inquiry

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Autologous CD34+-enriched hematopoietic stem and progenitor cells (Genenta Science)Phase 2 ClinicalGenenta Science SrlCarcinoma, Renal Cell; Glioblastoma; Multiple Myeloma
Details
CX-801CX-801Phase 1 ClinicalCytomx Therapeutics IncSolid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Nadofaragene firadenovecSCH-721015ApprovedSchering - Plough Sa, Fkd TherapiesAdstiladrinUnited StatesUrinary Bladder NeoplasmsFerring Pharmaceuticals A/S2022-12-16Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Mesothelioma
Details
  • Product Inquiry
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland